RE: Thats is one hell of a senior appointment8 Jun 2026 16:39
H1 2026: Completion of Phase I dose escalation and preliminary safety data.
Q3 2026: Initiation of combination therapy protocols and meeting a 40-patient enrollment target.
H2 2026: Comprehensive efficacy readouts for ovarian and prostate cancer trials.
Good staff hopefully leads to good results .
Outstanding